OncoMatch/Clinical Trials/NCT05147467

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Is NCT05147467 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies APG2575 for chronic lymphocytic leukemia.

Phase 2RecruitingAscentage Pharma Group Inc.NCT05147467Data as of May 2026

Treatment: APG2575 — The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.

Check if I qualify

Extracted eligibility criteria

Cancer type

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: BTK inhibitor — refractory, recurrent, or intolerant

Refractory, recurrent, or intolerant to BTK inhibitors

Must have received: immunochemotherapy — refractory, recurrent, or intolerant

Refractory, recurrent, or intolerant to...immunochemotherapy

Cannot have received: BCL2 inhibitor

Received Bcl-2 inhibitor treatment

Cannot have received: allogeneic hematopoietic stem cell transplantation

Exception: if within 24 months

Prior history of allogeneic hematopoietic stem cell transplantation...within 24 months

Cannot have received: autologous hematopoietic stem cell transplantation

Exception: if within 24 months

Prior history of...autologous hematopoietic stem cell transplantation within 24 months

Cannot have received: adoptive cell immunotherapy

Exception: if within 24 months

Prior history of...adoptive cell immunotherapy...within 24 months

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify